[Role of the Rho-kinase pathway in pulmonary arterial hypertension]

Nihon Yakurigaku Zasshi. 2014 Apr;143(4):178-81. doi: 10.1254/fpj.143.178.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives*
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / therapeutic use
  • Animals
  • Bosentan
  • Drug Therapy, Combination
  • Epoprostenol / analogs & derivatives
  • Epoprostenol / therapeutic use
  • Humans
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / genetics*
  • Hypertension, Pulmonary / physiopathology
  • Mice
  • Molecular Targeted Therapy*
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use*
  • Purines / therapeutic use
  • Rats
  • Signal Transduction / drug effects
  • Signal Transduction / genetics*
  • Signal Transduction / physiology*
  • Sildenafil Citrate
  • Sulfonamides / therapeutic use
  • Sulfones / therapeutic use
  • Vascular Resistance / drug effects
  • rho-Associated Kinases / antagonists & inhibitors*
  • rho-Associated Kinases / physiology*

Substances

  • Piperazines
  • Protein Kinase Inhibitors
  • Purines
  • Sulfonamides
  • Sulfones
  • beraprost
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • Sildenafil Citrate
  • Epoprostenol
  • rho-Associated Kinases
  • fasudil
  • Bosentan